Nordic Capital has agreed to acquire a majority share in corpuls to support the company’s next phase of growth, in partnership with the founding family.
Pasuwan Shutterstock
1005619948
acquisition
corpuls is an innovative medical technology company, specialising in emergency medical solutions and cardiac resuscitation with a key focus on the external defibrillator segment.
The founding family of corpuls is committed to a long-term partnership with Nordic Capital and will remain invested in the company and represented on the management board. Together, Nordic Capital and the founding family are dedicated to continuing to invest in innovation at the company’s site, furthering its telemedicine offering, accelerating its growth in the hospital segment and further expanding its international footprint.
corpuls develops medical products and solutions, including advanced life support defibrillators and monitoring devices, automated external defibrillators, chest compression devices as well as telemedicine and software solutions. The products are designed to support professional users, such as emergency medical professionals in delivering critical care to patients under demanding circumstances. corpuls was founded in 1982 and is headquartered in Kaufering, Germany.
The company has just acquired a new factory site near its headquarters on which an additional production facility is to be built. corpuls sells its products in more than 60 countries, posted revenues of €127 million in 2022 and employs 450 people in total. The company has recently been recognised in a study as the fastest growing SME in Germany with an impressive annual revenue growth rate of 26.5% between 2017 and 2021.
With its extensive expertise in the healthcare sector, Nordic Capital will help corpuls continue its successful growth trajectory. Nordic Capital has more than 30 years of experience in supporting the growth of innovative healthcare and technology companies globally and is an active investor in the DACH region. Healthcare, and especially medical technologies, is one of Nordic Capital’s key focus sectors since its establishment in 1989 and the investment in corpuls fully aligns with Nordic Capital’s focus on innovative, differentiated, and responsible healthcare companies.
Previous Nordic Capital investments include companies such as The Binding Site, a specialty diagnostics company, Equashield, a provider of closed system transfer devices designed to protect healthcare professionals from exposure to hazardous drugs, pharmaceutical company Advanz Pharma, and Sunrise Medical, a rehab mobility solutions company.
Klaus Stemple, CTO, corpuls, said: “We are excited to partner with Nordic Capital with the objective of jointly supporting the next stage of corpuls’ growth. Having attracted a leading investor like Nordic Capital is a testimony to the remarkable success of our company over the past years. They are the ideal partner for further developing corpuls, for solidifying our position as a leading technology supplier for cardiac resuscitation and emergency medical solutions, and for expanding into new markets. We share the same perspective about innovative high-quality products and continued strong growth of the company.”
Jonas Agnblad, partner, Nordic Capital Advisors, added: “We have followed and admired corpuls for many years and are impressed by the company’s product differentiation, based on strong innovation power, unique know-how in the organisation, outstanding customer feedback and a successful track record of growth. Nordic Capital greatly values the unique expertise that exists within corpuls and believes that investing in talent as well as staying true to corpuls’ roots and quality will be key to future success.”
The transaction is subject to customary closing conditions, including relevant regulatory approvals with completion being expected at the end of Q2 or the beginning of Q3 2023.
